Natarajan Sethuraman Sells 2,700 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,700 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $20.04, for a total value of $54,108.00. Following the transaction, the insider now owns 160,888 shares of the company’s stock, valued at $3,224,195.52. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, November 11th, Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock. The stock was sold at an average price of $20.01, for a total value of $28,194.09.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.24, for a total value of $9,144.00.

Entrada Therapeutics Trading Up 0.9 %

NASDAQ:TRDA opened at $19.96 on Thursday. Entrada Therapeutics, Inc. has a twelve month low of $10.75 and a twelve month high of $20.49. The company has a market cap of $746.90 million, a price-to-earnings ratio of 12.55 and a beta of -0.26. The stock has a fifty day simple moving average of $16.62 and a 200-day simple moving average of $15.85.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $94.69 million during the quarter, compared to the consensus estimate of $55.00 million. As a group, equities research analysts predict that Entrada Therapeutics, Inc. will post 1.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TRDA shares. HC Wainwright raised their price target on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. Oppenheimer lifted their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 6th.

Institutional Trading of Entrada Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TRDA. Renaissance Technologies LLC purchased a new position in shares of Entrada Therapeutics during the second quarter valued at $636,000. The Manufacturers Life Insurance Company increased its stake in shares of Entrada Therapeutics by 3.9% during the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after buying an additional 2,146 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Entrada Therapeutics during the first quarter valued at $79,000. Vanguard Group Inc. increased its stake in shares of Entrada Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after buying an additional 13,742 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Entrada Therapeutics by 427.6% during the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after buying an additional 11,965 shares during the period. 86.39% of the stock is currently owned by institutional investors.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.